Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

SML2369

Sigma-Aldrich

Tipelukast

≥98% (HPLC)

Synonym(s):

4-[6-Acetyl-3-[3-[(4-acetyl-3-hydroxy-2-propylphenyl)thio]propoxy]-2-propylphenoxy]butanoic acid, KCA-757, MN-001

Sign Into View Organizational & Contract Pricing

Select a Size

1 MG
€75.90
5 MG
€310.00

€75.90

Check Cart for Availability
All Photos(1)

Select a Size

Change View
1 MG
€75.90
5 MG
€310.00

About This Item

Empirical Formula (Hill Notation):
C29H38O7S
CAS Number:
125961-82-2
Molecular Weight:
530.67
MDL number:
MFCD00886138
UNSPSC Code:
51111800
NACRES:
NA.77

€75.90

Check Cart for Availability

Assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

CCCC1=C(SCCCOC2=C(CCC)C(OCCCC(O)=O)=C(C(C)=O)C=C2)C=CC(C(C)=O)=C1O

InChI

1S/C29H38O7S/c1-5-9-23-25(14-12-22(20(4)31)29(23)36-16-7-11-27(32)33)35-17-8-18-37-26-15-13-21(19(3)30)28(34)24(26)10-6-2/h12-15,34H,5-11,16-18H2,1-4H3,(H,32,33)

InChI key

KPWYNAGOBXLMSE-UHFFFAOYSA-N

Biochem/physiol Actions

Antifibrotic and anti-inflammatory Leukotriene D4 (LTD4) receptor antagonist and inhibitor of 5-lipoxygenase (5-LO) and phosphodiesterases PDE3 and PDE4.
Tipelukast is a Leukotriene D4 (LTD4) receptor antagonist and an inhibitor of 5-lipoxygenase (5-LO) and also phosphodiesterases PDE3 and PDE4. It has been found to have antifibrotic and anti-inflammatory activity. Tipelukast has been investigated as a possible treatment for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000202011
0000050948
0000050949
0000050948
0000050949

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Yoshio Sumida et al.
Journal of gastroenterology, 53(3), 362-376 (2017-12-17)
Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver disease worldwide, and there is no approved pharmacotherapy. The efficacy of vitamin E and pioglitazone has been established in nonalcoholic steatohepatitis (NASH), a progressive form of NAFLD. GLP-1RA and SGLT2
Nonalcoholic steatohepatitis (NASH) drugs market.
Sorcha Cassidy et al.
Nature reviews. Drug discovery, 15(11), 745-746 (2016-11-04)

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service